Please select the option that best describes you:

How would you treat a patient with emergence of EGFR C797S mutation at the time of progression on osimertinib given for EGFR T790M mutation?   

Would your choice of treatment change if the same patient was T790M negative and osimertinib was given as a first-line therapy?



Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more